Bernstein raises Centene stock price target to $90 on Medicaid outlook

Bernstein raised Centene Corp.'s (CNC) price target to $90 from $79, citing strong Q3 results and improved Medicaid prospects. The stock is up 102% in a year. Centene beat EPS estimates and raised full-year guidance, with revenue expected between $196.5B and $200.5B. Analysts highlight undervaluation and growth potential.

Original reporting
Published Nov 17, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNC
Bullish
medium confidence
Mentioned
$CNC
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CNCBullishLow
01

Why it matters

For traders, the actionable element is the broker’s raised price target and estimate revisions, which can influence positioning and near-term sentiment around managed care and Medicaid-linked earnings durability.

02

Market read

A bullish sell-side update tied to Medicaid recovery and MLR expectations, but it is not a new Centene corporate disclosure.

03

What to watch

The article cites a Q3 beat and guidance raises, but it does not quantify Medicaid policy/regulatory risks that could reverse recovery assumptions.

Relevance 4/10Novelty 3/10Timing: today, as the analyst target change hits the tape

Background

The piece reports Bernstein’s updated valuation and forecast assumptions for Centene, referencing Centene’s Q3 results and Medicaid recovery expectations.

Company-level read

Ticker impact

$CNCBullishMedium confidence
Context

Bernstein raised Centene’s price target to $90 and lifted EPS and revenue estimates, citing improved Medicaid recovery prospects and Q3 results.

Expected impact

Likely near-term support for the stock as traders price in the raised target and improved Medicaid recovery narrative.

Evidence & confidence

The article is an analyst target/estimate change tied to specific guidance revisions (EPS, revenue, MLR) and a Q3 beat, which typically moves sentiment even if it is not a fresh company disclosure.

Market effects

Reinforces positive sentiment for managed care names tied to Medicaid recovery and medical loss ratio normalization.

Limited, primarily US managed-care sentiment.

Low, largely domestic healthcare reimbursement dynamics.

Counterpoint

Analyst target hikes can lag underlying fundamentals; the key risk is whether Medicaid recovery and MLR improvements persist beyond the forecast window.

Key entities

  • Centene Corp.

    US managed care provider; subject of Bernstein’s raised price target and forecast revisions in the article.

  • Bernstein SocGen Group

    Brokerage raising Centene’s price target to $90 and adjusting EPS, revenue, and MLR expectations.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$CVSMed

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

High

Centene Surges 10.5% After Truist Securities Reiterates Buy

Centene Corporation's stock surged 10.5% to $74.56 on Wednesday, with a market cap of $37.3B, after Truist Securities, Wells Fargo, and JP Morgan raised their price targets by an average of 7.4%. Truist maintained a Buy rating, while Wells Fargo and JP Morgan adjusted their targets to $75 with Equal-Weight and Neutral ratings, respectively. The average price target is now $77, indicating potential upside.